Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of KK2430 in hematologic neoplasms
jRCT2031260064Phase 2Recruiting
- Sponsor
- Kyowa Kirin
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label, single-arm trial of KK2430 in hematopoietic malignancies, sponsored by Kyowa Kirin. Primary endpoints: Dose-limiting toxicities (DLT), Adverse events (AEs) and 3 more. Started May 2026; status: recruiting.
02
Drugs
KK2430
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on jRCT2031260064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260064.